Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.
Issue link: http://todaysveterinarypractice.epubxp.com/i/619503
Today's VeTerinary PracTice | January/February 2016 | tvpjournal.com elemenTs oF oncology Peer reviewed 60 10. Taylor lP. mechanism of brain tumor headache. Headache 2014; 54:772- 775. 11. Hall eJ. Radiobiology for the Radiologist, 7th ed. Philadelphia: Wolters Kluwer Health/lippincott Williams & Wilkins, 2012. 12. gillette el, larue sm, gillette sm. normal tissue tolerance and management of radiation injury. Semin Vet Med Surg (small anim) 1995; 10:209-213. 13. gillette el, mahler Pa, Powers Be, et al. late radiation injury to muscle and peripheral nerves. Int J Radiat Oncol Biol Phys 1995; 31:1309-1318. 14. King Jn, Hotz r, reagan el, et al. safety of oral robenacoxib in the cat. J Vet Pharmacol Ther 2012; 35(3):290-300. 15. Thamm dH, Vail dm. aftershocks of cancer chemotherapy: managing adverse effects. JAAHA 2007; 43:1-7. 16. Venable ro, saba cF, endicott mm, et al. dexrazoxane treatment of doxorubicin extravasation injury in four dogs. JAVMA 2012; 240:304- 307. 17. charney sc, Bergman PJ, Hohenhaus ae, et al. risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). JAVMA 2003; 222:1388-1393. 18. Best mP, Fry dr. incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007-2012). JAVMA 2013; 243:1025-1029. 19. miller KK, gorcey l, mclellan Bn. chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71:787-794. 20. anderson rT, Keating Kn, doll Ha, et al. The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology. Oncologist 2015; 20:831-838. 21. Vail dm, Kravis ld, cooley aJ, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39:410-416. 22. Teske e, rutteman gr, Kirpenstein J, et al. a randomized controlled study into the effcacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. Vet Comp Oncol 2011; 9:283-289. 23. Vail dm, chun r, Thamm dH, et al. effcacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4:1567-1571. 24. anderson r, Jatoi a, robert c, et al. search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFsr) caused by the multikinase inhibitors (mKis). Oncologist 2009; 14:291-302. 25. lacouture me, reilly lm, gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19:1955-1961. 26. london ca, Hannah al, Zadovoskaya r, et al. Phase i dose-escalating study of sU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003; 9:2755-2768. 27. Bernabe lF, Portela r, nguyen s, et al. evaluation of the adverse event profle and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res 2013; 9:190. 28. Hahn Ka, ogilvie g, oglivie g, et al. masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22:1301- 1309. 29. smrkovski oa, essick l, rohrbach BW, et al. masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet Comp Oncol 2013. 30. gilson sd. Principles of surgery for cancer palliation and treatment of metastases. Clin Tech Small Anim Pract 1998; 13:65-69. 31. lawrence Ja, Forrest lJ, Turek mm, et al. Proof of principle ocular sparing in dogs with sinonasal tumors treated with intensity modulated radiation therapy. Vet Radiol Ultrasound 2010; 51(5):561-570. 32. goblirsch m, mathews W, lynch c, et al. radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 2004; 161:228- 234. 33. Fan Tm, charney sc, de lorimier lP, et al. double-blind placebo- controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med 2009; 23:152-160. January/February 2016 | tvpjournal.com 60 Color Coding 0n Dog Chewables Ivermectin Pyrantel Foil Backing Weight Per Month Content Content and Carton Up to 25 lb 1 68 mcg 57 mg Blue 26 to 50 lb 1 136 mcg 114 mg Green 51 to 100 lb 1 272 mcg 227 mg Brown chewables ®HEARTGARD and the Dog & Hand logo are registered trademarks of Merial. ©2015 Merial, Inc., Duluth, GA. All rights reserved. HGD15PRETESTTRADEADS (01/16). CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. INDICATIONS: For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Diroflaria immitis) for a month (30 days) after infection and for the treatment and control of ascarids (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense). DOSAGE: HEARTGARD ® Plus (ivermectin/pyrantel) should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) of body weight. The recommended dosing schedule for prevention of canine heartworm disease and for the treatment and control of ascarids and hookworms is as follows: HEARTGARD Plus is recommended for dogs 6 weeks of age and older. For dogs over 100 lb use the appropriate combination of these chewables. ADMINISTRATION: Remove only one chewable at a time from the foil-backed blister card. Return the card with the remaining chewables to its box to protect the product from light. Because most dogs fnd HEARTGARD Plus palatable, the product can be offered to the dog by hand. Alternatively, it may be added intact to a small amount of dog food. The chewable should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended. HEARTGARD Plus should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's frst exposure to mosquitoes. The fnal dose must be given within a month (30 days) after the dog's last exposure to mosquitoes. When replacing another heartworm preventive product in a heartworm disease preventive program, the frst dose of HEARTGARD Plus must be given within a month (30 days) of the last dose of the former medication. If the interval between doses exceeds a month (30 days), the effcacy of ivermectin can be reduced. Therefore, for optimal performance, the chewable must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with HEARTGARD Plus and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms. Monthly treatment with HEARTGARD Plus also provides effective treatment and control of ascarids (T. canis, T. leonina) and hookworms (A. caninum, U. stenocephala, A. braziliense). Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites. EFFICACY: HEARTGARD Plus Chewables, given orally using the recommended dose and regimen, are effective against the tissue larval stage of D.immitis for a month (30 days) after infection and, as a result, prevent the development of the adult stage. HEARTGARD Plus Chewables are also effective against canine ascarids (T. canis, T. leonina) and hookworms (A. caninum, U. stenocephala, A. braziliense). ACCEPTABILITY: In acceptability and feld trials, HEARTGARD Plus was shown to be an acceptable oral dosage form that was consumed at frst offering by the majority of dogs. PRECAUTIONS: All dogs should be tested for existing heartworm infection before starting treatment with HEARTGARD Plus which is not effective against adult D. immitis. Infected dogs must be treated to remove adult heartworms and microflariae before initiating a program with HEARTGARD Plus. While some microflariae may be killed by the ivermectin in HEARTGARD Plus at the recommended dose level, HEARTGARD Plus is not effective for microflariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microflariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microflariae. Keep this and all drugs out of the reach of children. In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans. Store between 68°F - 77°F (20°C - 25°C). Excursions between 59°F - 86°F (15°C - 30°C) are permitted. Protect product from light. ADVERSE REACTIONS: In clinical feld trials with HEARTGARD Plus, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported following the use of HEARTGARD: Depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation. SAFETY: HEARTGARD Plus has been shown to be bioequivalent to HEARTGARD, with respect to the bioavailability of ivermectin. The dose regimens of HEARTGARD Plus and HEARTGARD are the same with regard to ivermectin (6 mcg/kg). Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target use level) than dogs of other breeds. At elevated doses, sensitive dogs showed adverse reactions which included mydriasis, depression, ataxia, tremors, drooling, paresis, recumbency, excitability, stupor, coma and death. HEARTGARD demonstrated no signs of toxicity at 10 times the recommended dose (60 mcg/kg) in sensitive Collies. Results of these trials and bioequivalency studies, support the safety of HEARTGARD products in dogs, including Collies, when used as recommended. HEARTGARD Plus has shown a wide margin of safety at the recommended dose level in dogs, including pregnant or breeding bitches, stud dogs and puppies aged 6 or more weeks. In clinical trials, many commonly used fea collars, dips, shampoos, anthelmintics, antibiotics, vaccines and steroid preparations have been administered with HEARTGARD Plus in a heartworm disease prevention program. In one trial, where some pups had parvovirus, there was a marginal reduction in effcacy against intestinal nematodes, possibly due to a change in intestinal transit time. HOW SUPPLIED: HEARTGARD Plus is available in three dosage strengths (See DOSAGE section) for dogs of different weights. Each strength comes in convenient cartons of 6 and 12 chewables. For customer service, please contact Merial at 1-888-637-4251. elemenTs oF oncology